The impact of plasma exchange (PE) on the treatment of severe Guillain-Barre syndrome (GBS)was studied by comparing all the 16 patients treated with PE in a London teaching hospital between January 1985 and August 1987, with 64 historical controls drawn from a series of patients observed during a prospective study in South East England in 1983 and 1984. There were no GBS-related deaths in the PE treated group but seven in the historical controls (2pc=O.39). The median duration of ventilation was only 20 days (range 7-64) in the PE group compared with 36 days (range 14-365) in the surviving patients in the control group (2P=0.06, 95% confidence interval of difference in medians -36 to 0 days). The PE group walked earlier without aid (median 55.5 compared with 86 days, 2P=0.04, 95% confidence interval of difference in medians -88 to -2 days). Three months after the onset of neuropathy all PE treated patients were able to walk with support or better, whereas 19 of the surviving historical controls were unable to walk even with support (2P=0.009). The costs of PE were offset by savings in intensive care unit and hospital expenditure.
Introduction
Guillain-Barre syndrome (GBS) is an acute demyelinating polyradiculoneuropathy, which may have an immunological pathogenesis. Evidence of antibodies to nerve antigens and demyelinating serum factors':" has provided a rationale for the use of plasma exchange (PE). Since the first report of successful PE in GBS by Brettle et at. in 1978 6 , several reports of small and uncontrolled trials 6 - 14 and recent randomized prospective trials [15] [16] [17] [18] [19] . have been published. Evidence from these reports favoured the use of PE early in severe GBS20. Persuaded by this evidence we began to use PE m severe GBS in January 1985. We have analysed our subsequent experience to check whether PE confers the benefits predicted by the randomized control trials 15-19 and to assess its cost effectiveness.
Plasma was exchanged using a Haemonetics 30 intermittent flow cell separator preferably via arm veins, until a plasma discard of 50 ml/kg had been achieved. Fi ve such exchanges were done over a period of 7-10 days. Plasma was replaced with a combination of human albumin solution and crystalloids. Patients were assessed on a disability scale (O=healthy; 1= minor symptoms; 2=able to walk 5 m without support; 3=able to walk 5 m with support; 4=confined to bed or wheelchair; 5= requiring assisted ventilation; 6=dead). Patients were assessed at two, three and four weeks after completion and then after three, six and 12 months. Specific enquiries were made about the dates when each patient reached functional grades, 3, 2 and 1. This report includes all patients treated between January 1985 and July 1987. These patients were compared with all those patients from a prospective study of GBS in South East England in 1983-1984 22 who had disease of similar severity (grades 4 or 5) when first studied and who were not treated with PE.
Data were not normally distributed and so the groups were compared with the Mann-Whitney U test instead of a t-test. Differences between proportions were tested with Fisher's exact test. Two-tailed tests of significance were used.
Results
During the study period we admitted 21 patients with GBS. Four were so mildly affected that they did not fulfil the study criteria. These patients recovered completely within 24, 26, 49 and 61 days. A fifth mildly affected patient was exchanged because he was deteriorating rapidly, and seemed as if he would become unable to walk. Progression stopped after the first of five PEs and complete recovery had occurred within 60 days. Sixteen patients fulfilled the study criteria and were given plasma exchange. Sixty-four out of 100 patients from a prospective study of GBS during the previous two years had not been treated with PE and fulfilled the study criteria 22. The main Table 1 
. Clinical features
Patients and methods In January 1985 we adopted the policy of treating patients who fulfilled recognized diagnostic criteria for GBS21 with PE, provided that they had such severe disease that they were unable to walk and could be treated within two weeks of the onset of neuropathy. Patients with a history of previous attacks of GBS, progressive course lasting more than four weeks, chronic relapsing demyelinating polyradiculoneuropathy, or positive serum test for hepatitis B surface antigen were excluded. features of these groups were similar (Table 1 ) except that the time from onset of neuropathy to becoming unable to walk even with aid (grade 4) in the PE group was half that of historical controls (2P=0.02).
Number of patients
Plasma exchange was started within 3-12 days of onset of GBS. The mean (SD) volume of plasma exchanged per patient was 13.25(2.01)litres. Complications related to the procedure were anaemia requiring blood transfusion in one patient, and deep vein thrombosis following exchange via the femoral vein in another patient.
There were no deaths in the PE group related to GBS whereas seven of the control group died, four due to cardiac arrest and one each due to pulmonary embolism, respiratory failure and septicaemia. Six of the patients who died had been ventilated for 5, 5, 13, 42, 43 and 315 days. The larger number of deaths in the historical controls was not significant (2P=0.39). The patients who died were not included in analyses of times to reach grades 4, 3 or 2 (on the ground that they could never achieve these grades).
The patients treated with PE came offthe ventilator earlier and improved to grade 3 (aided walking) and grade 2 (unaided walking) sooner than the surviving historical controls ( Table 2 ). By the end of the third month after the onset of neuropathy they had also attained better clinical grades (Table 3) . After three months, 19 out of 58 of the surviving control patients and none of the PE group had failed to improve to grade 3 (2P=0.009).
Discussion
We have demonstrated that it is practicable to plasma exchange patients with GBS in a teaching hospital setting. The benefits to the PE group compared with historical controls are similar to those reported in recent randomized controlled trials 16 -19 • A study with historical controls cannot carry the same weight as a controlled trial in evaluating the benefit of PE. Furthermore we are comparing patients treated by plasma exchange in our single unit in 1985-1987 with those treated in many hospitals in South East England in 1983-1984. We were unable to compare the results in our unit in 1983-1984 because we only admitted three eligible patients then. The reason that the number increased from 1985 onwards was the introduction of a deliberate policy of accepting patients into our unit for PE. To critics who may accuse us of selectively admijsing patients destined to have a better prognosis, we would say that we were endeavouring to choose severely affected patients who had become bedbound within a week and who our previous experience suggested would have a worse prognosis than those who had a slower disease onset 22 ,23. This policy is reflected in the shorter time from onset to grade 4 in the PE treated patients than the historical controls ( Table 1) .
The shortening of time in the intensive care unit and hospital predicted by our results from the use of PE has been used as the basis of a comparison of its cost effectiveness ( Table 4 ). The costs of albumin and disposable plastic ware for a single exchange amount to £300 and operator costs to £200. The total cost of five exchanges is about £2500. To this might be added the expense of transport to and from the hospital which in the worst case of two journeys from the south coast is £1400. For the ventilated GBS patient these costs can be offset against the savings from reduced time spent in the intensive care unit, which can reasonably be assumed to be similar to the reduced time on the ventilator (reduction in median of 16 days). If we take the total cost of a day in our intensive care unit, £456, as the basis of our calculations, the amount saved is £7296. If we adopt the argument that the staffing costs might not be reduced by leaving the intensive care unit bed empty, only the intensive care unit bed consumable costs, £116, would be saved and the amount saved becomes £1856. For the severely affected GBS patient not requiring ventilation savings would accrue not from less intensive care unit time but from the shortening of hospital stay. We have based our calculations on the median time taken to reach grade 3 (aided walking) which was 24 days less in the PE than control group. We have assumed that the reduction in hospital stay (for which we lack information for the controls) would be similar to the reduction in time to reach grade 3. The use of PE would result in savings of £3696 per case based on consumable and staffing costs of £154 a day and £816 per case based only on -Assuming reduction in intensive care unit stay is equivalent to reduction in time on ventilator. ... Assuming reduction in hospital stay is equivalent to reduction in time to walk with aid. ,. Based on worst case of an ambulance journey from the south coast to London with a nurse and doctor in attendance.
consumable costs of £34 a day. Calculation of these savings assumes that the bed is left empty: if it is filled the use of PE has at least contributed to the productivity of the unit.
On the credit side must be considered the financial advantage to the patient of returning to work earlier and to the DHSS of lesser sickness benefit payments. The non-financial advantages to the patient include less time on the ventilator, in the intensive care unit, in hospital and unable to fulfil their usual role in society. The non-financial disadvantages are the discomfort of the procedure and its asso&ted risks. The commonest complications, which are usually of minor degree, result from inadequate control of blood volume and allergic or febrile reactions to the replacement materials. However, fatal complications have occurred with an incidence of about 3 in 10000 procedures: severe anaphylactic reactions to plasma manifesting as acute pulmonary oedema or circulatory collapse, and systemic complications related to indwelling venous lines, such as bleeding or septicaemia, have been implicated in these cases 24 ,25. The risks may be reduced by using 5% human albumin solution as the replacement fluid and, whenever possible, by inserting new, superficial venous catheters for each procedure.
If the financial and humanitarian advantages ofPE for severe GBS are accepted 19 ,20 we need to provide a nationwide system for looking after patients with severe GBS in units which can provide both ventilatory intensive care and plasma exchange. At present few units have both these facilities and administrative delays often lead to treatment being postponed to a stage when it is less effective. It might be possible to achieve the same end by providing a mobile PE unit in each Region. However this would lose the advantage of concentrating the care of patients with severe GBS in a small number of units which would become experienced in the management of their special intensive care problems. Such a policy might reduce the mortality from Guillain-Barre syndrome which was 12% in the UK in 1983-1984 22 • To put this policy into action each neurological centre and intensive care unit needs to devise a means for providing PE for patients with GBS. It will be helpful in soliciting the support of our finance officers to be able to argue that using PE will actually save the health service money. 
